Youngkyu Moon1, Si Young Choi1, Jae Kil Park2, Kyo Young Lee3. 1. Department of Thoracic & Cardiovascular Surgery, Eunpyeong St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea. 2. Department of Thoracic & Cardiovascular Surgery, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea. 3. Department of Hospital Pathology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
Abstract
BACKGROUND: Patients with stage IB non-small cell lung cancer (NSCLC) with poor prognostic factors can be treated selectively with postoperative adjuvant chemotherapy. The aim of this study was to identify the prognostic factors of stage IB NSCLC according to the new 8th edition of the tumor, node, and metastasis (TNM) staging system. METHODS: From 2005 to 2016, 211 patients who were diagnosed with stage IB NSCLC according to the 8th edition of the TNM staging system underwent anatomical pulmonary resection (lobectomy or bilobectomy). We analyzed the outcomes of patients receiving adjuvant chemotherapy. The risk factors for prognosis after surgery were also analyzed for NSCLC stage IB. RESULTS: Differences between the 5-year recurrence-free-survival (RFS) rates (71.4% vs. 60.2%, P=0.173) and the 5-year disease-specific-survival (DSS) rates (88.0% vs. 81.4%, P=0.437) obtained by patients receiving surgical treatment only versus patients receiving both surgery and adjuvant chemotherapy, retrospectively, were not significant. Multivariate analysis was conducted to identify the risk factors for recurrence and cancer-related death. Lymphovascular invasion was an independent risk factor for both recurrence and cancer-related death [hazard ratio (HR) =2.045, P=0.020; HR =3.150, P=0.048, respectively). CONCLUSIONS: Lymphovascular invasion was the only prognostic factor identified in patients with 8th edition stage IB NSCLC. Adjuvant chemotherapy was not an effective treatment for patients with stage IB NSCLC. The efficacy of adjuvant chemotherapy for stage IB patients with lymphovascular invasion should be evaluated in a future study. 2019 Journal of Thoracic Disease. All rights reserved.
BACKGROUND: Patients with stage IB non-small cell lung cancer (NSCLC) with poor prognostic factors can be treated selectively with postoperative adjuvant chemotherapy. The aim of this study was to identify the prognostic factors of stage IB NSCLC according to the new 8th edition of the tumor, node, and metastasis (TNM) staging system. METHODS: From 2005 to 2016, 211 patients who were diagnosed with stage IB NSCLC according to the 8th edition of the TNM staging system underwent anatomical pulmonary resection (lobectomy or bilobectomy). We analyzed the outcomes of patients receiving adjuvant chemotherapy. The risk factors for prognosis after surgery were also analyzed for NSCLC stage IB. RESULTS: Differences between the 5-year recurrence-free-survival (RFS) rates (71.4% vs. 60.2%, P=0.173) and the 5-year disease-specific-survival (DSS) rates (88.0% vs. 81.4%, P=0.437) obtained by patients receiving surgical treatment only versus patients receiving both surgery and adjuvant chemotherapy, retrospectively, were not significant. Multivariate analysis was conducted to identify the risk factors for recurrence and cancer-related death. Lymphovascular invasion was an independent risk factor for both recurrence and cancer-related death [hazard ratio (HR) =2.045, P=0.020; HR =3.150, P=0.048, respectively). CONCLUSIONS: Lymphovascular invasion was the only prognostic factor identified in patients with 8th edition stage IB NSCLC. Adjuvant chemotherapy was not an effective treatment for patients with stage IB NSCLC. The efficacy of adjuvant chemotherapy for stage IB patients with lymphovascular invasion should be evaluated in a future study. 2019 Journal of Thoracic Disease. All rights reserved.
Entities:
Keywords:
8th edition of tumor, node, and metastasis staging system (8th edition of TNM staging system); Prognostic factor; non-small cell lung cancer (NSCLC)
Authors: Gary M Strauss; James E Herndon; Michael A Maddaus; David W Johnstone; Elizabeth A Johnson; David H Harpole; Heidi H Gillenwater; Dorothy M Watson; David J Sugarbaker; Richard L Schilsky; Everett E Vokes; Mark R Green Journal: J Clin Oncol Date: 2008-09-22 Impact factor: 44.544
Authors: William D Travis; Hisao Asamura; Alexander A Bankier; Mary Beth Beasley; Frank Detterbeck; Douglas B Flieder; Jin Mo Goo; Heber MacMahon; David Naidich; Andrew G Nicholson; Charles A Powell; Mathias Prokop; Ramón Rami-Porta; Valerie Rusch; Paul van Schil; Yasushi Yatabe Journal: J Thorac Oncol Date: 2016-04-21 Impact factor: 15.609
Authors: Ramón Rami-Porta; Vanessa Bolejack; John Crowley; David Ball; Jhingook Kim; Gustavo Lyons; Thomas Rice; Kenji Suzuki; Charles F Thomas; William D Travis; Yi-Long Wu Journal: J Thorac Oncol Date: 2015-07 Impact factor: 15.609
Authors: David Jonathan Heineman; Martijn Geert Ten Berge; Johannes Marlene Daniels; Michaël Ignatius Versteegh; Perla Jacqueline Marang-van de Mheen; Michael Wilhelmus Wouters; Wilhelmina Hendrika Schreurs Journal: Ann Thorac Surg Date: 2016-09-21 Impact factor: 4.330
Authors: Peter Goldstraw; Kari Chansky; John Crowley; Ramon Rami-Porta; Hisao Asamura; Wilfried E E Eberhardt; Andrew G Nicholson; Patti Groome; Alan Mitchell; Vanessa Bolejack Journal: J Thorac Oncol Date: 2016-01 Impact factor: 15.609